ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Background:
- Irinotecan is a drug that is used to treat colon or rectal cancer. It affects the
deoxyribonucleic acid (DNA) of growing cancer cells. It is most often used with other
chemotherapy drugs. Researchers want to test it with an experimental drug, ISIS 183750. They
want to see if the drugs are a safe and effective treatment for advanced solid tumors or
colorectal cancer that has not responded to other treatments.
Objectives:
- To test the safety and effectiveness of ISIS 183750 with irinotecan for advanced solid
tumors or colorectal cancer.
Eligibility:
- Individuals at least 18 years of age who have solid tumors or colorectal cancer that has
not responded to other treatments.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will also be collected. Tumor tissue samples may be collected as well before and
after treatment. Imaging studies will also be performed.
- Participants will take ISIS 183750 once a week for 28-day cycles of treatment. On the
first cycle, they will also have ISIS 183750 on days 3 and 5.
- Participants will take irinotecan every second week, beginning on day 15 of the first
cycle.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Treatment will continue as long as the cancer does not grow and the side effects are not
severe.